Skip to main content

Table 2 Prevalence of interleukin-1 receptor antagonist gene polymorphisms (IL-1RA) and serostatus of CMV and their combination in patients with and without cardiovascular events during follow-up

From: Prognostic value of interleukin-1 receptor antagonist gene polymorphism and cytomegalovirus seroprevalence in patients with coronary artery disease

  Patients with Cardiovascular Event (n = 60) Patients without Cardiovascular Event (n = 240) p-value
IL-1 RA    
- othera 55 (91.7%) 215 (89.6%)  
- Il-1RN*2 5 (8.3%) 25 (10.4%) 0.6
CMV-serostatusb    
- negative 29 (49.2%) 110 (46.8%)  
- positive 30 (50.9%) 125 (53.2%) 0.7
IL-1 RA and CMV serostatus    
- IL-othera and CMV-negative 27 (45.8%) 96 (40.9%)  
- IL-othera and CMV-positive 27 (45.8%) 114 (48.5%)  
- Il-1RN*2 and CMV-negative 2 (3.4%) 14 (6.0%)  
- Il-1RN*2 and CMV-positive 3 (5.1%) 11 (4.7%) 0.8c
  1. a = all other alleles summarized (IL-1RN*4, IL-1RN*5, IL-1RN*3) except IL-RN*2
  2. b = in 6 patients quantitative determination of IgG was not available
  3. c = Fisher exact test